SEC EDGAR 8-KNov 5$COGT

Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2026 Financial Results

Cogent Biosciences, Inc. (COGT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2026 Financial Results Preparing for anticipated bezuclastinib launch in GIST; PDUFA action date November 30, 2026 NonAdvSM PDUFA target action date December 30, 2026; AdvSM PDUFA target action d

Original reporting

SEC EDGAR 8-K

Published Nov 5, 2026, 9:20 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Nov 5, 2026, 9:21 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefEarnings

Primary signal

$COGT

Neutral

medium confidence

Mentioned

$COGT

Relevance

7/10

AlphAI data visualization · based on SEC EDGAR 8-K

Decision brief

The 30-second read

$COGTNeutralMed

Why it matters

The disclosure provides fresh financial metrics and forward‑looking milestones that could influence investor sentiment and short‑term price action.

Market read

Primary earnings release for a micro‑cap biotech with upcoming FDA dates; relevant for sector‑focused traders.

What to watch

Rising R&D expenses and G&A growth could pressure margins despite cash strength.

Relevance 7/10Novelty 7/10Timing: today

Background

Cogent Biosciences filed an 8‑K announcing Q3 2026 results, cash position, and upcoming regulatory milestones for its lead drug bezuclastinib.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$COGTNeutralMedium confidence

Context

Cogent Biosciences reported Q3 2026 financial results and business highlights, including $791.1M cash and upcoming FDA PDUFA dates for bezuclastinib.

Expected impact

modest upside as market prices in the upcoming FDA approvals and cash runway

Evidence & confidence

New earnings numbers and forward‑looking milestones are fresh information, but the impact depends on future FDA decisions.

Market effects

Sector

Biotech sector may benefit from multiple pending FDA decisions, supporting peer valuations.

Regional

U.S. biotech investors see added confidence in cash‑rich pipelines.

Global

Limited to biotech investors; no broad market effect.

Counterpoint

What could challenge this read

If FDA approvals are delayed, the cash runway may not translate into near‑term price gains.

Key entities

company
Cogent Biosciences, Inc.
Biotech firm developing bezuclastinib and other targeted therapies.

Read at source ← All news

$INOHighAI 9/10

KXCO's FDA ontology ranked INO-3107 first. After the approval, Inovio (INO) traded over 300% higher after hours. Three more FDA decisions are on our radar.

Inovio Pharmaceuticals (INO) received FDA approval for its drug VOCERYQ (INO-3107), leading to a 351.7% after-hours trading surge and a 215.0% gain in the next session. KXCO's AI ontology predicted this outcome. Three other FDA decisions are upcoming for BridgeBio (BBIO), Cogent (COGT), and Praxis (PRAX).

livetradingnews.comNov 3

$COGTHighAI 8/10

Stifel reiterates Cogent stock Buy rating on ESMO data

Stifel reiterated a Buy rating and $45 price target for Cogent Biosciences (COGT), citing positive ESMO conference data. The stock has risen 91% in the past year. Analysts expect 40% upside from the current price. Cogent's bezuclastinib drug showed promise in trials, with FDA decisions pending for multiple indications. Analysts maintain Strong Buy consensus with targets ranging from $45 to $62.

investing.comOct 27

$COGTHighAI 8/10

Cogent's Bezuclastinib NDA Accepted For Advanced Systemic Mastocytosis; PDUFA Set For June 2027

Cogent Biosciences (COGT) announced FDA acceptance of its NDA for Bezuclastinib to treat Advanced Systemic Mastocytosis, with a PDUFA target date of June 2027. The NDA is supported by APEX trial data showing a 65% overall response rate and 79% 12-month progression-free survival. The FDA has not identified any review issues. COGT is also advancing NDAs for other indications. The stock is currently trading at $33.49, up 0.24%.

rttnews.comSep 15

$COGTMed

Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2026 Financial Results

Cogent Biosciences, Inc. (COGT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2026 Financial Results On track for potential approval of bezuclastinib for GIST patients (PDUFA November 30) and NonAdvSM patients (PDUFA December 30) later this year; AdvSM New Drug Applicatio

SEC EDGAR 8-KAug 10

$COGTMed

Cogent Bioscience (COGT) Files New Drug Application For Bezuclastinib

Cogent Biosciences (NASDAQ:COGT) said it filed a New Drug Application with the U.S. FDA for bezuclastinib to treat advanced systemic mastocytosis, citing encouraging results from its APEX key trial. CEO Andrew Robbins said the company is working with the FDA on three submissions and expects initial approvals by end-2026.

yahoo.comJul 15

$TDGMedAI 8/10

TransDigm (TDG) Q4 2026 Earnings Call Transcript

TransDigm (TDG) reported Q4 2026 earnings, highlighting double-digit growth in all major end markets. Revenue and EBITDA exceeded guidance, with defense delivering three consecutive quarters of double-digit growth. The company repurchased $940 million in stock, totaling $2.75 billion for the year. TransDigm deployed $7 billion in M&A and share repurchases, acquiring several companies.

finance.yahoo.comNov 10